August 14, 2018
Software as a Medical Device – also referred to as SaMD – is one of the fastest growing innovations in the medical device industry. As with any technology that experiences rapid adoption, challenges related to IP protection often follow. In this series, we’re taking a closer look at IP considerations that SaMD developers should be aware of.
In this podcast, Finnegan attorneys Eric Raciti and Cory Bell explore nuances of IP law that life sciences companies should consider when developing an SaMD.
Conference
4th Spring Pharmaceutical Synchrotron X-Ray Powder Diffraction Workshop
June 10-11, 2024
Basel
Webinar
Obviousness of Biologics Inventions: Strategies for Biologics Claims in the U.S., Europe, and China
May 28,2024
Webinar
Webinar
Building a Strong ADC Patent Portfolio – From Prosecution and Litigation Perspectives
May 15, 2024
Webinar
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.